CreativeOne Wealth LLC Increases Stake in Bristol-Myers Squibb (NYSE:BMY)

CreativeOne Wealth LLC boosted its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 27.5% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 33,692 shares of the biopharmaceutical company’s stock after purchasing an additional 7,272 shares during the period. CreativeOne Wealth LLC’s holdings in Bristol-Myers Squibb were worth $1,743,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of BMY. Atria Investments Inc grew its position in Bristol-Myers Squibb by 13.3% during the 1st quarter. Atria Investments Inc now owns 138,838 shares of the biopharmaceutical company’s stock valued at $7,536,000 after purchasing an additional 16,270 shares during the last quarter. PGGM Investments boosted its holdings in shares of Bristol-Myers Squibb by 4.7% during the 1st quarter. PGGM Investments now owns 103,065 shares of the biopharmaceutical company’s stock valued at $5,589,000 after acquiring an additional 4,656 shares during the last quarter. Cetera Investment Advisers boosted its holdings in shares of Bristol-Myers Squibb by 262.1% during the 1st quarter. Cetera Investment Advisers now owns 574,683 shares of the biopharmaceutical company’s stock valued at $31,165,000 after acquiring an additional 415,984 shares during the last quarter. Cetera Advisors LLC boosted its holdings in shares of Bristol-Myers Squibb by 122.3% during the 1st quarter. Cetera Advisors LLC now owns 270,340 shares of the biopharmaceutical company’s stock valued at $14,661,000 after acquiring an additional 148,729 shares during the last quarter. Finally, Pathway Financial Advisers LLC purchased a new stake in shares of Bristol-Myers Squibb during the 1st quarter valued at about $60,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Bristol-Myers Squibb

In other news, SVP Phil M. Holzer sold 700 shares of the business’s stock in a transaction on Monday, November 4th. The shares were sold at an average price of $55.62, for a total value of $38,934.00. Following the transaction, the senior vice president now owns 11,760 shares of the company’s stock, valued at approximately $654,091.20. The trade was a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Samit Hirawat bought 1,830 shares of the stock in a transaction dated Friday, November 1st. The stock was bought at an average cost of $54.67 per share, for a total transaction of $100,046.10. Following the acquisition, the executive vice president now directly owns 62,109 shares of the company’s stock, valued at approximately $3,395,499.03. This represents a 3.04 % increase in their position. The disclosure for this purchase can be found here. Insiders own 0.09% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. TD Cowen raised their price target on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a report on Monday, October 7th. Daiwa Capital Markets raised shares of Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a report on Wednesday, November 13th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $50.00 price target on shares of Bristol-Myers Squibb in a report on Friday, October 18th. Wolfe Research assumed coverage on shares of Bristol-Myers Squibb in a research note on Friday, November 15th. They issued a “peer perform” rating on the stock. Finally, Morgan Stanley increased their price objective on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the stock an “underweight” rating in a research note on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, two have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $54.07.

Bristol-Myers Squibb Price Performance

Shares of NYSE:BMY opened at $59.27 on Friday. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $61.08. The company has a market capitalization of $120.21 billion, a P/E ratio of -16.51, a P/E/G ratio of 15.77 and a beta of 0.44. The firm’s 50 day simple moving average is $54.41 and its two-hundred day simple moving average is $48.12.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.31. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The business had revenue of $11.89 billion for the quarter, compared to the consensus estimate of $11.26 billion. During the same quarter in the previous year, the firm earned $2.00 earnings per share. The company’s revenue for the quarter was up 8.4% on a year-over-year basis. Research analysts expect that Bristol-Myers Squibb will post 0.93 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Friday, October 4th were issued a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 4.05%. The ex-dividend date was Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -66.85%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.